메뉴 건너뛰기




Volumn 23, Issue 7, 2013, Pages 1935-1944

Recent developments in targeting protein misfolding diseases

Author keywords

Chaperone; Cystic fibrosis; Gaucher disease; Protein misfolding; Proteostasis; Serum amyloid P (SAP); Toxic oligomer

Indexed keywords

ALPHA GALACTOSIDASE; CELASTROL; CHAPERONE; ENZYME; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; GONADORELIN; ISOFAGOMINE; IVACAFTOR; LUMACAFTOR; OLIGOMER; PYRROLIDINE DERIVATIVE; RHODOPSIN; RO 63 8695; SERUM AMYLOID A; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

EID: 84875230719     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.01.089     Document Type: Review
Times cited : (36)

References (109)
  • 9
    • 84875224607 scopus 로고    scopus 로고
    • Cystic Fibrosis Mutation Database.
    • Cystic Fibrosis Mutation Database. http://www.genet.sickkids.on.ca/cftr/ app.
  • 19
    • 84875231042 scopus 로고    scopus 로고
    • Maestro, Version 9.3, Schrödinger, LLC: New York, NY, 2012.
    • Maestro, Version 9.3, Schrödinger, LLC: New York, NY, 2012.
  • 24
    • 77249176209 scopus 로고    scopus 로고
    • F. Becq Drugs 70 2010 241
    • (2010) Drugs , vol.70 , pp. 241
    • Becq, F.1
  • 27
    • 84875209882 scopus 로고    scopus 로고
    • ClinicalTrials.gov Identifier: NCT01531673; A Phase 2, Multicenter, Double-Blinded, Placebo Controlled, 3-Part Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/VX-770 Cotherapy in Subjects with Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
    • http://clinicaltrials.gov/ct2/show/NCT01531673; ClinicalTrials.gov Identifier: NCT01531673; A Phase 2, Multicenter, Double-Blinded, Placebo Controlled, 3-Part Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/VX-770 Cotherapy in Subjects with Cystic Fibrosis, Homozygous for the F508del CFTR Mutation.
  • 29
    • 84875221592 scopus 로고    scopus 로고
    • Accelrys Software Inc. Accelrys Software San Diego
    • Accelrys Software Inc. Discovery Studio 3.5 2010 Accelrys Software San Diego
    • (2010) Discovery Studio 3.5
  • 92
    • 84875227308 scopus 로고    scopus 로고
    • A Phase 1 Dose Escalation Study to Investigate the Pharmacokinetics, P., Safety, and Tolerability of Single Intravenous Doses of GSK2315698A in Healthy Volunteers (Clinical Trials.gov Identifier: NCT01323985).
    • A Phase 1 Dose Escalation Study to Investigate the Pharmacokinetics, P., Safety, and Tolerability of Single Intravenous Doses of GSK2315698A in Healthy Volunteers (Clinical Trials.gov Identifier: NCT01323985).
  • 93
    • 84875228142 scopus 로고    scopus 로고
    • 1273794: Academic Drug Discovery: Programmes and Collaborations (Part II), L., UK. Norman PIDdb Meeting Report 2012 Posted on: 22March2012. 1273794: Academic Drug Discovery: Programmes and Collaborations (Part II), London, UK. Norman PIDdb Meeting Report 2012 Posted on: 22 March 2012: London, UK, 2012.
    • 1273794: Academic Drug Discovery: Programmes and Collaborations (Part II), L., UK. Norman PIDdb Meeting Report 2012 Posted on: 22March2012. 1273794: Academic Drug Discovery: Programmes and Collaborations (Part II), London, UK. Norman PIDdb Meeting Report 2012 Posted on: 22 March 2012: London, UK, 2012.
  • 99


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.